ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · IEX Real-Time Price · USD
-0.07 (-4.17%)
At close: Dec 4, 2023, 2:29 PM
+0.02 (1.49%)
After-hours: Dec 4, 2023, 4:00 PM EST

Company Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally.

It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.

The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.

In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.

The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel.

Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes.

Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain.

It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts.

The company was incorporated in 1983 and is headquartered in Victoria, Canada.

ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies logo
Country Canada
Founded 1983
IPO Date Jan 3, 2017
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Dr. Jennifer Lynne Bath Ph.D.

Contact Details

880 - 580 Hornby Street
Vancouver, A1 V6C3B6
British Columbia, Canada
Phone 6048060626

Stock Details

Ticker Symbol IPA
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
CIK Code 0001715925
CUSIP Number 45257F200
ISIN Number CA45257F2008
SIC Code 2834

Key Executives

Name Position
Dr. Jennifer Lynne Bath Ph.D. Chief Executive Officer, President and Non-Independent Director
Brad McConn Chief Financial Officer
Dr. Ilse Roodink Chief Scientific Officer
David E. Orton Chief Operating Officer
Carla Dahl Vice President of Marketing
Dr. Barry Neil Duplantis Vice President of Client Relations

Latest SEC Filings

Date Type Title
Nov 27, 2023 6-K Report of foreign issuer
Nov 16, 2023 6-K Report of foreign issuer
Nov 13, 2023 6-K Report of foreign issuer
Oct 25, 2023 6-K Report of foreign issuer
Oct 23, 2023 6-K Report of foreign issuer
Oct 20, 2023 6-K Report of foreign issuer
Sep 26, 2023 6-K Report of foreign issuer
Sep 25, 2023 6-K Report of foreign issuer
Sep 19, 2023 6-K Report of foreign issuer
Sep 18, 2023 6-K Report of foreign issuer